1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow AZD9592: new trials by email Literature Review of AZD9592 trials Research Report on AZD9592
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First in Human Study of AZD9592 in Solid Tumors AZD9592, Osimertinib, 5-Fluorouracil (5-FU) - Advanced Solid Tumours, Carcinoma Non-small Cell Lung | Phase 1 | Active not recruiting | AstraZeneca | 190 | 2022-12-21 | 2026-09-25 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasms (1)
AstraZeneca (1)
Australia (1) · Canada (1) · China (1) · France (1) · Italy (1) · Japan (1) · Malaysia (1) · South Korea (1) · Spain (1) · Taiwan (1) · United States (1)